Denali Therapeutics (US.DNLI)
Capital Allocation Audit · Period: 2015 – 2026
Key Metrics
US.DNLI · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 101.9% | → |
| ROE | -13.9% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.04 | ↑ |
| Gross Margin | - | → |
US.DNLI (Denali Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 101.9% → ROE -13.9% ↓ Cash Conversion - → D/E Ratio 0.04 ↑ Gross Margin - →
Key Metrics
US.DNLI (Denali Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 101.9% →ROE -13.9% ↓Cash Conversion - →D/E Ratio 0.04 ↑Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies